Dementia treatment update

Geriatric Nursing

Volumn 26, Issue 2, 2005, Pages 74-78

  Buffum, Marti D ^a,b   Buffum, John C ^c  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA TOCOPHEROL; AMIODARONE; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANXIOLYTIC AGENT; CALCIUM; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DILTIAZEM; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; HORMONE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; MEMANTINE; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NOOTROPIC AGENT; PIRACETAM; RIFAMPICIN; RIVASTIGMINE; SELEGILINE; SUXAMETHONIUM; TACRINE; UNINDEXED DRUG; VACCINE;

AGED; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; BODY WEIGHT DISORDER; BRADYCARDIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; COST BENEFIT ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM ULCER; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG PREFERENCE; DRUG SAFETY; DRUG SYNTHESIS; DRUG WITHDRAWAL; FATIGUE; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; INCONTINENCE; INSOMNIA; MUSCLE CRAMP; NAUSEA; RISK BENEFIT ANALYSIS; SYNCOPE; UNPLEASANT DREAM; VACCINATION; VOMITING; WEIGHT REDUCTION;

AGED; CHOLINESTERASE INHIBITORS; DEMENTIA; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; GERIATRIC ASSESSMENT; HUMANS; INDANS; INTESTINAL ABSORPTION; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PATIENT SELECTION; PHENYLCARBAMATES; PIPERIDINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 16844373796     PISSN: 01974572     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gerinurse.2005.01.003     Document Type: Article

References (23)

1. Hebert LE Scherr PA Bienias JL et al. Alzheimer disease in the U.S. population: Prevalence estimates using the 2000 Census Arch Neurol 60 2003 1119-1122
2. Etminan M Gill S Samii A Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: Systematic review and meta-analysis of observational studies BMJ 327 2003 1-5
3. Martyn C Anti-inflammatory drugs and Alzheimer's disease. Evidence implying a protective effect is as yet tentative BMJ 327 2003 353-354
4. Gasparini L Ongini E Wenk G Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: Old and new mechanisms of action J Neurochem 91 2004 521-536
5. Evans JG Wilcock G Birks J Evidence-based pharmacotherapy of Alzheimer's disease Int J Neuropsychopharmacol 7 2004 351-369
6. The Cochrane Database of Systematic Reviews. The Cochrane Library Web site: http://www.cochrane.org Accessed December 15, 2004
7. Cummings JL Alzheimer's disease N Engl J Med 351 2004 56-67
8. Drugs and therapies. Alzheimer's Association Web site: http://www.alzforum.org/dis/tre/drt/default.asp Accessed December 17, 2004
9. Drugs in clinical trials. Alzheimer's Association Web site: http://www.alzforum.org/dis/tre/drc/ Accessed December 17, 2004
10. Forest Laboratories. Package insert. Namenda® (memantine hydrochloride). 2003
11. Novartis Pharmaceuticals. Package insert. Exelonreg; (rivastigmine tartrate). 2004
12. Areosa Sastre A, McShane R, Sherriff F. Memantine for dementia. The Cochrane Database of Systematic Reviews 2004;4:CD003154.pub2. DOI: 10.1002/14651858.CD 003154.pub2
13. Orgogozo J Rigaud A Stoffler A et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia Stroke 33 2002 1834-1839
14. Pantoni L Treatment of vascular dementia: Evidence from trials with non-cholinergic drugs J Neurol Sci 226 2004 67-70
15. Tariot PN Farlow MR Grossberg GT et al. Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. A randomized controlled trial JAMA 291 2004 317-324
16. AD2000 Collaborative Group Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomized double-blind trial Lancet 363 2004 2105-2115
17. Schneider LS Commentary. AD2000: Donepezil in Alzheimer's disease Lancet 363 2004 2100-2101
18. Forest Laboratories. FDA accepts supplemental New Drug Application filing to expand Namenda's® indication to include treatment of mild Alzheimer's disease. Press release, November 15, 2004. http://www.frx.com Accessed January 1, 2005
19. Pomara N, Peskind ER, Potkin SG. Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial [abstract 01-05-04]. Presented at the 9th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, July 2004
20. Tariot PN, Doody R, Peskind E. Memantine treatment for mild to severe Alzheimer's disease: Clinical trials summary [abstract P1-021]. Poster presented at the 9th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, July 2004
21. Semla TP Beizer JL Higbee MD Geriatric dosage handbook 10th ed. 2005 Lexi-Comp Hudson, OH
22. Cummings JL Use of cholinesterase inhibitors in clinical practice. Evidence-based recommendations Am J Geriatr Psychiatry 11 2003 131-145
23. Lanctôt KL Herrmann N Yau KK et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: A meta-analysis CMAJ 169 2003 557-564